Source comparison
CJC-1295 No DAC & Ipamorelin Safety: Clinical Comparison
CJC-1295 No DAC GHRH receptor agonist ~30 minutes Injection site reaction (10–15%), flushing (5–8%) None documented 90-day trials, no serious adverse events Ipamorelin Selective ghrelin receptor agonist ~2 hours Injection site reaction (10%), headache (3–5%) N
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- GHRH receptor agonist
- ~30 minutes
- Injection site reaction (10–15%), flushing (5–8%)
- None documented
- 90-day trials, no serious adverse events
- Ipamorelin
- Selective ghrelin receptor agonist
- ~2 hours
- Injection site reaction (10%), headache (3–5%)
- None at doses ≤200mcg
- 16-week trials, 2.4% discontinuation (non-peptide reasons)
- GHRP-2
- Non-selective ghrelin agonist
- Injection site reaction, hunger, cortisol elevation (20–40%)
- Significant
- Limited long-term data
- Exogenous GH
- Direct replacement
- ~2.5 hours
- Oedema, joint pain, insulin resistance risk
- Variable
- Decades of clinical use, known long-term risks
- CJC-1295 + Ipamorelin
- Dual GHRH + ghrelin pathway
- Pulsatile (30 min–2 hrs)
- Combined: injection site reaction, flushing, mild water retention
- No formal Phase III combo trial; individual peptide safety well-documented
- Professional Assessment
- CJC-1295 No DAC and Ipamorelin demonstrate the most favorable safety-to-efficacy ratio among peptide secretagogues based on current trial evidence. The absence of cortisol elevation, short half-lives allowing physiological reset, and lack of serious adverse events across hundreds of participants make this combination the current standard in research protocols requiring pulsatile GH stimulation.